• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·002019.SZ
Share

Yifan Pharmaceutical Co., Ltd. Stocks

CN¥ 10.22Last Updated 26.05.2026

Issuer Rating

5/7
Performance

Average

Risk

Low

Recommendation

Hold

Market Cap

CN¥ 1.83B

CN¥ 10.22
Key Takeaways

Risk factor

Strong trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Yifan Pharmaceutical Co., Ltd. produces and sells drugs and medicines in China and internationally. It provides drugs across gynecology, pediatrics, orthopedics, and dermatology therapeutic areas; therapeutic infusion solutions; and pantothenic acid and Provitamin B5 products. The company also provides Chinese traditional medicines, women's health products, and blood tumor drugs. In addition, it offers APIs, including feed additives/animal health products, skin and hair care ingredients, functional food additives, and fine chemicals; and PBAT/PBS biodegradable resins and PVB films. The company was formerly known as Yifan Xinfu Pharmaceutical Co., Ltd. and changed its name to Yifan Pharmaceutical Co., Ltd. in October 2016. Yifan Pharmaceutical Co., Ltd. was founded in 2000 and is based in Hangzhou, China.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, overvalued o

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 002019.SZ is 18 and suggests 77% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.05.2026 15:58

Morning in New York: geopolitics and macro statistics sway volatility

28.05.2026 15:12

Traders are upping the ante against small-cap companies. What do they fear?

28.05.2026 14:10

Nebius shares soared: its shareholder turned out to be an important AI investor who worked at OpenAI

28.05.2026 13:45

Rallying 35%: report and Amazon partnership revive interest in Snowflake stock

28.05.2026 12:53

Meta has started selling AI subscriptions to chatbot and social networks. The shares jumped by 4%

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026